Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer.
10.4046/trd.2014.76.5.218
- Author:
Myoung Rin PARK
1
;
Yeon Hee PARK
;
Jae Woo CHOI
;
Dong Il PARK
;
Chae Uk CHUNG
;
Jae Young MOON
;
Hee Sun PARK
;
Sung Soo JUNG
;
Ju Ock KIM
;
Sun Young KIM
;
Jeong Eun LEE
Author Information
1. Department of Public Health Administration, The Province of Chungcheongnam-do, Hongseong, Korea.
- Publication Type:Original Article
- Keywords:
Small Cell Lung Carcinoma;
Prognosis;
Disease-Free Survival
- MeSH:
Diagnosis;
Disease-Free Survival*;
Drug Therapy;
Humans;
Male;
Multivariate Analysis;
Neoplasm Staging;
Prognosis;
Small Cell Lung Carcinoma*;
Survival Rate
- From:Tuberculosis and Respiratory Diseases
2014;76(5):218-225
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Small cell lung cancer (SCLC) is an extremely aggressive tumor with a poor clinical course. Although many efforts have been made to improve patients' survival rates, patients who survive longer than 2 years after chemotherapy are still very rare. We examined the baseline characteristics of patients with long-term survival rates in order to identify the prognostic factors for overall survivals. METHODS: A total of 242 patients with cytologically or histologically diagnosed SCLC were enrolled into this study. The patients were categorized into long- and short-term survival groups by using a survival cut-off of 2 years after diagnosis. Cox's analyses were performed to identify the independent factors. RESULTS: The mean patient age was 65.66 years, and 85.5% were males; among the patients, 61 of them (25.2%) survived longer than 2 years. In the multivariate analyses, CRP (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.25-6.06; p=0.012), TNM staging (HR, 3.29; 95% CI, 1.59-6.80; p=0.001), and progression-free survival (PFS) (HR, 11.14; 95% CI, 2.98-41.73; p<0.001) were independent prognostic markers for poor survival rates. CONCLUSION: In addition to other well-known prognostic factors, this study discovered relationships between the long-term survival rates and serum CRP levels, TNM staging, and PFS. In situations with unfavorable conditions, the PFS would be particularly helpful for managing SCLC patients.
